Research programme: pain and inflammation therapeutics - Xel

Drug Profile

Research programme: pain and inflammation therapeutics - Xel

Alternative Names: XEL 002BG; XEL 002BI; XEL 002BP; XEL 002LG; XEL 004FP

Latest Information Update: 07 Jan 2016

Price : $50

At a glance

  • Originator Xel Pharmaceuticals
  • Class Alkaloids
  • Mechanism of Action Serotonin modulators; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation; Pain

Most Recent Events

  • 07 Jan 2016 Discontinued - Preclinical for Inflammation in USA (Parenteral)
  • 07 Jan 2016 Discontinued - Preclinical for Inflammation in USA (Topical)
  • 07 Jan 2016 Discontinued - Preclinical for Inflammation in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top